EVOLUS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
EVOLUS, INC. (EOLS) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $2.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2026-08-05
- EVOLUS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2026-06-30 was $2.49M, a 21.40% increase year-over-year.
- EVOLUS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2026-03-31 was $1.89M, a 19.96% decline year-over-year.
- EVOLUS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- EVOLUS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2025-09-30 was $1.79M, a 10.92% decline year-over-year.
- EVOLUS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2025 was $6.20M, a 16.65% decline from fiscal 2024.
- EVOLUS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2024 was $7.44M, a 34.39% increase from fiscal 2023.
- EVOLUS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2023 was $5.54M, a 32.31% increase from fiscal 2022.
- EVOLUS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2022 was $4.18M, a 35.13% increase from fiscal 2021.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $2.49M 10-Q · filed 2026-08-05 | $4.38M 10-Q · filed 2026-08-05 | $4.38M derived: sum of 3 quarters · filed 2026-08-05 | $6.17M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $1.89M 10-Q · filed 2026-05-04 | $1.89M derived: sum of 2 quarters · filed 2026-05-04 | $3.68M derived: sum of 3 quarters · filed 2026-05-04 | $5.73M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $1.79M derived: sum of 2 quarters · filed 2026-03-03 | $3.84M derived: sum of 3 quarters · filed 2026-08-05 | $6.20M 10-K · filed 2026-03-03 | |
| 2025-09-30 | $1.79M 10-Q · filed 2025-11-05 | $3.84M derived: sum of 2 quarters · filed 2026-08-05 | $6.20M 10-Q · filed 2025-11-05 | $8.03M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $2.05M 10-Q · filed 2026-08-05 | $4.42M 10-Q · filed 2026-08-05 | $6.25M derived: sum of 3 quarters · filed 2026-08-05 | $8.25M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $2.37M 10-Q · filed 2026-05-04 | $4.19M derived: sum of 2 quarters · filed 2026-05-04 | $6.20M derived: sum of 3 quarters · filed 2026-05-04 | $7.98M derived: sum of 4 quarters · filed 2026-05-04 | |
| 2024-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $3.83M derived: sum of 2 quarters · filed 2026-03-03 | $5.61M derived: sum of 3 quarters · filed 2026-03-03 | $7.44M 10-K · filed 2026-03-03 | |
| 2024-09-30 | $2.00M 10-Q · filed 2025-11-05 | $3.78M derived: sum of 2 quarters · filed 2025-11-05 | $5.61M 10-Q · filed 2025-11-05 | $7.11M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2024-06-30 | $1.78M 10-Q · filed 2025-08-05 | $3.61M 10-Q · filed 2025-08-05 | $5.11M derived: sum of 3 quarters · filed 2026-03-03 | $6.58M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2024-03-31 | $1.83M 10-Q · filed 2025-05-07 | $3.33M derived: sum of 2 quarters · filed 2026-03-03 | $4.81M derived: sum of 3 quarters · filed 2026-03-03 | $6.06M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2023-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.98M derived: sum of 2 quarters · filed 2026-03-03 | $4.23M derived: sum of 3 quarters · filed 2026-03-03 | $5.54M 10-K · filed 2026-03-03 | |
| 2023-09-30 | $1.48M 10-Q · filed 2024-11-06 | $2.73M derived: sum of 2 quarters · filed 2024-11-06 | $4.04M 10-Q · filed 2024-11-06 | $5.05M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2023-06-30 | $1.25M 10-Q · filed 2024-07-31 | $2.56M 10-Q · filed 2024-07-31 | $3.58M derived: sum of 3 quarters · filed 2025-03-04 | $4.69M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2023-03-31 | $1.31M 10-Q · filed 2024-05-07 | $2.32M derived: sum of 2 quarters · filed 2025-03-04 | $3.44M derived: sum of 3 quarters · filed 2025-03-04 | $4.45M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2022-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $2.13M derived: sum of 2 quarters · filed 2025-03-04 | $3.15M derived: sum of 3 quarters · filed 2025-03-04 | $4.18M 10-K · filed 2025-03-04 | |
| 2022-09-30 | $1.11M 10-Q · filed 2023-11-07 | $2.13M derived: sum of 2 quarters · filed 2023-11-07 | $3.17M 10-Q · filed 2023-11-07 | $3.97M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $1.02M 10-Q · filed 2023-08-02 | $2.06M 10-Q · filed 2023-08-02 | $2.86M derived: sum of 3 quarters · filed 2023-08-02 | $3.64M derived: sum of 4 quarters · filed 2023-08-02 | |
| 2022-03-31 | $1.04M 10-Q · filed 2023-05-09 | $1.84M derived: sum of 2 quarters · filed 2023-05-09 | $2.62M derived: sum of 3 quarters · filed 2023-05-09 | $3.61M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $802.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $1.58M derived: sum of 2 quarters · filed 2023-03-08 | $2.57M derived: sum of 3 quarters · filed 2023-03-08 | $3.10M 10-K · filed 2023-03-08 | |
| 2021-09-30 | $783.00K 10-Q · filed 2022-11-08 | $1.77M derived: sum of 2 quarters · filed 2022-11-08 | $2.29M 10-Q · filed 2022-11-08 | $2.29M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | $983.00K 10-Q · filed 2022-08-02 | $1.51M 10-Q · filed 2022-08-02 | $1.51M derived: sum of 3 quarters · filed 2022-08-02 | $1.74M derived: sum of 4 quarters · filed 2022-08-02 | |
| 2021-03-31 | $529.00K 10-Q · filed 2022-05-10 | $528.00K derived: sum of 2 quarters · filed 2022-05-10 | $761.00K derived: sum of 3 quarters · filed 2022-05-10 | $1.08M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $232.00K derived: sum of 2 quarters · filed 2022-03-03 | $547.00K derived: sum of 3 quarters · filed 2022-03-03 | $1.13M 10-K · filed 2022-03-03 | $1.13M 10-K · filed 2021-03-25 |
| 2020-09-30 | $233.00K 10-Q · filed 2021-11-02 | $548.00K derived: sum of 2 quarters · filed 2021-11-02 | $1.13M 10-Q · filed 2021-11-02 | $1.53M derived: sum of 4 quarters · filed 2021-11-02 | |
| 2020-06-30 | $315.00K 10-Q · filed 2021-08-04 | $898.00K 10-Q · filed 2021-08-04 | $1.29M derived: sum of 3 quarters · filed 2021-08-04 | $1.36M derived: sum of 4 quarters · filed 2021-08-04 | |
| 2020-03-31 | $583.00K 10-Q · filed 2021-05-12 | $978.00K derived: sum of 2 quarters · filed 2021-05-12 | $1.05M derived: sum of 3 quarters · filed 2021-05-12 | ||
| 2019-12-31 | $395.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $464.00K derived: sum of 2 quarters · filed 2021-03-25 | $9.68M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $69.00K 10-Q · filed 2020-10-29 | $9.28M 10-Q · filed 2020-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |